BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,368,578 | +25.9% | 1,341,243 | -17.9% | 0.04% | +27.6% |
| Q2 2023 | $28,087,359 | -24.1% | 1,632,986 | -26.8% | 0.03% | -27.5% |
| Q1 2023 | $37,006,908 | +79.8% | 2,232,021 | -17.4% | 0.04% | +73.9% |
| Q4 2022 | $20,580,279 | -12.2% | 2,700,824 | +14.5% | 0.02% | -17.9% |
| Q3 2022 | $23,439,000 | +5.4% | 2,358,069 | -3.7% | 0.03% | +7.7% |
| Q2 2022 | $22,232,000 | -12.2% | 2,448,459 | -1.9% | 0.03% | +8.3% |
| Q1 2022 | $25,335,000 | +18.1% | 2,496,028 | +94.1% | 0.02% | +33.3% |
| Q4 2021 | $21,452,000 | +174.7% | 1,286,089 | +672.0% | 0.02% | +157.1% |
| Q3 2021 | $7,808,000 | -24.1% | 166,592 | -1.3% | 0.01% | -22.2% |
| Q2 2021 | $10,286,000 | +548.1% | 168,734 | +555.0% | 0.01% | +350.0% |
| Q1 2021 | $1,587,000 | -51.4% | 25,759 | -77.1% | 0.00% | -60.0% |
| Q1 2020 | $3,265,000 | – | 112,589 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |